Currently submitted to: JMIR Public Health and Surveillance
Date Submitted: Jul 16, 2026
Open Peer Review Period: Jul 16, 2026 - Sep 10, 2026
(closed for review but you can still tweet)
NOTE: This is an unreviewed Preprint
Warning: This is a unreviewed preprint (What is a preprint?). Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn (a note "no longer under consideration" will appear above).
Peer review me: Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period (in this case, a "Peer Review Me" button to sign up as reviewer is displayed above). All preprints currently open for review are listed here. Outside of the formal open peer-review period we encourage you to tweet about the preprint.
Citation: Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author).
Final version: If our system detects a final peer-reviewed "version of record" (VoR) published in any journal, a link to that VoR will appear below. Readers are then encourage to cite the VoR instead of this preprint.
Settings: If you are the author, you can login and change the preprint display settings, but the preprint URL/DOI is supposed to be stable and citable, so it should not be removed once posted.
Submit: To post your own preprint, simply submit to any JMIR journal, and choose the appropriate settings to expose your submitted version as preprint.
Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.
Understanding How AIDS Drug Assistance Programs Support Medication Adherence: A Qualitative Study of the State Health Department Perspective
ABSTRACT
Background:
AIDS Drug Assistance Programs (ADAPs) are a critical safety net within the federal Ryan White HIV/AIDS Program. ADAPs are operated by state and territorial health departments and provide HIV medication access and insurance assistance for low-income people with HIV (PWH). However, the most recent qualitative study assessment of ADAPs was over 14 years ago.
Objective:
The purpose of this study was to better understand administrative, programmatic, clinical, and financial considerations that enable ADAPs to support adherence to HIV medications and ultimately achieve viral suppression, treating uninterrupted structural access to medications as a proximate determinant of downstream adherence behavior.
Methods:
We conducted a secondary qualitative analysis of interviews with state health department HIV program leaders and ADAP staff; participation was at the state level, with 16 states and 33 individual participants enrolled using maximum variance sampling. Coding was guided by the Exploration, Preparation, Implementation, and Sustainment (EPIS).
Results:
Our secondary analysis identified three domains of ADAP programmatic and policy decisions that support medication adherence: eligibility policies (income thresholds, recertification requirements, and re-enrollment flexibilities), formulary design (open vs. limited formularies, inclusion of newer long-acting therapies, and non-ART medications), and pharmacy access policies (network breadth, dispensing location, and multi-month dispensing). Across each domain, programs described facilitators that reduced medication interruptions and barriers that created gaps in ART access for low-income PWH.
Conclusions:
ADAPs play a central role in supporting medication adherence for low-income PWH through concrete programmatic and policy decisions. Flexible eligibility policies, broad formularies, and accessible pharmacy networks each reduce barriers to uninterrupted ART access. These findings are particularly timely: as of early 2026, at least two ADAPs have established waiting lists, and multiple states have reduced financial eligibility thresholds or formulary coverage in response to budget pressures. The policies described in this study as facilitators of adherence are the same policies being curtailed. Given this study’s findings, removal of these programs features would be expected to reduce the medication adherence and viral suppression gains ADAPs have achieved for the low-income PWH they serve.
Citation
Request queued. Please wait while the file is being generated. It may take some time.
Copyright
© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.